Daniele Generali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniele Generali has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alberto D'Angelo
Department of Medicine, Northern General Hospital, Sheffield S5 7AT, UK
1 shared publication Alberto Friziero
Acute Care Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Azienda Ospedale Università Padova, Italy
1 shared publicationArianna Vittori
Acute Care Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Azienda Ospedale Università Padova, Italy
1 shared publication- Daniele Generali
Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy
1 shared publication - Giandomenico Roviello
Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence
1 shared publication Gianfranco Da Dalt
Acute Care Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Azienda Ospedale Università Padova, Italy
1 shared publication
Latest Publications
- Open Access
- 9 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1684301
Strangulated cholecystitis in an umbilical hernia: world-first case report
Background: Strangulated umbilical hernia and acute cholecystitis are among the most common surgical emergencies, with operative management remaining the cornerstone of treatment. This study describes, to our knowledge, the first documented case worldwide of acute cholecystitis strangulated within an umbilical hernia. Case presentation: A 97-year-old woman with a history of recurrent choledocholithiasis presented to the Acute Care Department with abdominal pain localized to the mesogastrium and an irreducible, tender periumbilical mass. Abdominal computed tomography scan described a strangulated intestinal loop, prompting urgent surgical intervention. Surprisingly, exploratory laparotomy revealed an acute cholecystitis strangulated within the umbilical hernia, along with marked dilation of the common bile duct measuring up to 2 cm. Thus, a cholecystectomy and common bile duct exploration were performed, revealing a 2 cm non-obstructive gallstone at the ampulla of Vater, which was successfully extracted. A T-tube was then placed for biliary drainage, and the abdominal wall was closed primarily. The patient was discharged on postoperative day 14 in fair overall clinical condition and the subsequent follow-up was regular. Conclusion: This case underscores the importance of maintaining a high index of suspicion for atypical hernia contents and highlights the need for individualized surgical decision-making. Gallbladder herniation, though rare, can lead to diagnostic challenges. Successful management requires both technical expertise and sound clinical judgment in urgent settings.
- 9 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1684301
Open AccessStrangulated cholecystitis in an umbilical hernia: world-first case report
Background: Strangulated umbilical hernia and acute cholecystitis are among the most common surgical emergencies, with operative management remaining the cornerstone of treatment. This study describes, to our knowledge, the first documented case worldwide of acute cholecystitis strangulated within an umbilical hernia. Case presentation: A 97-year-old woman with a history of recurrent choledocholithiasis presented to the Acute Care Department with abdominal pain localized to the mesogastrium and an irreducible, tender periumbilical mass. Abdominal computed tomography scan described a strangulated intestinal loop, prompting urgent surgical intervention. Surprisingly, exploratory laparotomy revealed an acute cholecystitis strangulated within the umbilical hernia, along with marked dilation of the common bile duct measuring up to 2 cm. Thus, a cholecystectomy and common bile duct exploration were performed, revealing a 2 cm non-obstructive gallstone at the ampulla of Vater, which was successfully extracted. A T-tube was then placed for biliary drainage, and the abdominal wall was closed primarily. The patient was discharged on postoperative day 14 in fair overall clinical condition and the subsequent follow-up was regular. Conclusion: This case underscores the importance of maintaining a high index of suspicion for atypical hernia contents and highlights the need for individualized surgical decision-making. Gallbladder herniation, though rare, can lead to diagnostic challenges. Successful management requires both technical expertise and sound clinical judgment in urgent settings.
- Open Access
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Breast Cancer (BC) is the second most common type of cancer worldwide and displays the highest cancer-related mortality among women worldwide. Targeted therapies have revolutionized the way BC has been treated in recent decades, improving the life expectancies of millions of women. Among the different molecular pathways that have been of interest for the development of targeted therapies are the Cyclin-Dependent Kinases (CDK). CDK inhibitors are a class of molecules that already exist in nature and those belonging to the Cyclin dependent kinase inhibitors family INK4 that specifically inhibit CDK4/6 proteins. CDK4/6 inhibitors specifically block the transition from the G1 to the S phase of the cell cycle by dephosphorylation of the retinoblastoma tumor suppressor protein. In the past four years, the CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, received their first FDA approval for the treatment of Hormone Receptor (HR)-positive and Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer after showing significant improvements in progression-free survival in the PALOMA-1, MONALEESA-2 and the MONARCH-2 randomized clinical trials, respectively. After the encouraging results from these clinical trials, CDK4/6 inhibitors have also been investigated in other BC subtypes. In HER2-positive BC, a combination of CDK4/6 inhibitors with HER2-targeted therapies showed promise in preclinical studies and their clinical evaluation is ongoing. Moreover, in triple-negative BC, the efficacy of CDK4/6 inhibitors has been investigated in combination with other targeted therapies or immunotherapies. This review summarizes the molecular background and clinical efficacy of CDK4/6 inhibitors as single agents or in combination with other targeted therapies for the treatment of BC. Future directions for ongoing clinical trials and predictive biomarkers will be further debated.
Open AccessUpdates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Breast Cancer (BC) is the second most common type of cancer worldwide and displays the highest cancer-related mortality among women worldwide. Targeted therapies have revolutionized the way BC has been treated in recent decades, improving the life expectancies of millions of women. Among the different molecular pathways that have been of interest for the development of targeted therapies are the Cyclin-Dependent Kinases (CDK). CDK inhibitors are a class of molecules that already exist in nature and those belonging to the Cyclin dependent kinase inhibitors family INK4 that specifically inhibit CDK4/6 proteins. CDK4/6 inhibitors specifically block the transition from the G1 to the S phase of the cell cycle by dephosphorylation of the retinoblastoma tumor suppressor protein. In the past four years, the CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, received their first FDA approval for the treatment of Hormone Receptor (HR)-positive and Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer after showing significant improvements in progression-free survival in the PALOMA-1, MONALEESA-2 and the MONARCH-2 randomized clinical trials, respectively. After the encouraging results from these clinical trials, CDK4/6 inhibitors have also been investigated in other BC subtypes. In HER2-positive BC, a combination of CDK4/6 inhibitors with HER2-targeted therapies showed promise in preclinical studies and their clinical evaluation is ongoing. Moreover, in triple-negative BC, the efficacy of CDK4/6 inhibitors has been investigated in combination with other targeted therapies or immunotherapies. This review summarizes the molecular background and clinical efficacy of CDK4/6 inhibitors as single agents or in combination with other targeted therapies for the treatment of BC. Future directions for ongoing clinical trials and predictive biomarkers will be further debated.